The Role of Chemotherapy in Patients With HER2-Negative Isolated Locoregional Recurrence of Breast Cancer: A Multicenter Retrospective Cohort Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Kyoungmin | - |
dc.contributor.author | Sim, Sung Hoon | - |
dc.contributor.author | Kang, Eun Joo | - |
dc.contributor.author | Seo, Jae Hong | - |
dc.contributor.author | Chae, Heejung | - |
dc.contributor.author | Lee, Keun Seok | - |
dc.contributor.author | Kim, Ji-Yeon | - |
dc.contributor.author | Ahn, Jin Seok | - |
dc.contributor.author | Im, Young-Hyuck | - |
dc.contributor.author | Park, Seri | - |
dc.contributor.author | Park, Yeon Hee | - |
dc.contributor.author | Park, In Hae | - |
dc.date.accessioned | 2021-11-23T01:58:41Z | - |
dc.date.available | 2021-11-23T01:58:41Z | - |
dc.date.created | 2021-08-30 | - |
dc.date.issued | 2021-03-05 | - |
dc.identifier.issn | 2234-943X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/128419 | - |
dc.description.abstract | Background: The role of chemotherapy for isolated locoregional recurrence (iLRR) of breast cancer has not been firmly established after local therapies. Methods: We performed a multicenter, retrospective analysis to evaluate the clinical implications of chemotherapy in breast cancer patients with HER2-negative iLRR. Results: Of a total of 277 patients, 146 (52.7%) received chemotherapy for iLRR. Median follow-up duration was 56.1 months. Eighty-six (31.0%) patients had luminal B-like and 100 (36.1%) had TNBC iLRR. There was a trend of longer disease free survival (DFS) in the chemotherapy group (4-year DFS: 70.4 vs. 59.5%, HR = 0.68, 95% CI 0.45-1.02, log-rank p = 0.059). When adjusted with clinically relevant factors, DFS was significantly prolonged with chemotherapy (adjusted HR = 0.61, 95% CI 0.40-0.94, p = 0.023). Subgroup analyses for DFS showed patients with disease free interval (DFI) <5 years or prior chemotherapy had a benefit from chemotherapy (adjusted HR = 0.57, p = 0.018; adjusted HR = 0.51, p = 0.005, respectively). Regarding the molecular subtypes, a longer DFS with chemotherapy was observed both in luminal B-like (4-year DFS: 77.8 vs. 55.0%, HR = 0.51, 95% CI 0.27-0.99, log-rank p = 0.048) and in TNBC patients (4-year DFS: 61.9 vs. 42.8%, HR = 0.49, 95% CI 0.24-1.02, log-rank p = 0.056), but not in luminal A-like. Conclusions: The chemotherapy for iLRR of breast cancer should be individualized for each patient, considering DFI, prior chemotherapy, and molecular subtypes. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | FRONTIERS MEDIA SA | - |
dc.title | The Role of Chemotherapy in Patients With HER2-Negative Isolated Locoregional Recurrence of Breast Cancer: A Multicenter Retrospective Cohort Study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kang, Eun Joo | - |
dc.contributor.affiliatedAuthor | Seo, Jae Hong | - |
dc.contributor.affiliatedAuthor | Park, In Hae | - |
dc.identifier.doi | 10.3389/fonc.2021.653243 | - |
dc.identifier.scopusid | 2-s2.0-85102880613 | - |
dc.identifier.wosid | 000630332500001 | - |
dc.identifier.bibliographicCitation | FRONTIERS IN ONCOLOGY, v.11 | - |
dc.relation.isPartOf | FRONTIERS IN ONCOLOGY | - |
dc.citation.title | FRONTIERS IN ONCOLOGY | - |
dc.citation.volume | 11 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordAuthor | breast cancer | - |
dc.subject.keywordAuthor | isolated locoregional recurrence | - |
dc.subject.keywordAuthor | molecular subtype | - |
dc.subject.keywordAuthor | chemotherapy | - |
dc.subject.keywordAuthor | disease free survival | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.